Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay
of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Prostate cancers (PCs) with loss of the potent tumor suppressors TP53 and RB1 exhibit poor
outcomes. TP53 and RB1 also influence cell plasticity and are frequently lost in PCs with …

Sexually dimorphic traits are common among mammals and are specified during
development through the deployment of sex-specific genetic programs. Because little is …

Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of
multiple genes including MYC, and supraphysiological androgen is effective in some …

Deletion of the gene encoding the chromatin remodeler CHD1 is among the most common
alterations in prostate cancer (PCa); however, the tumor-suppressive functions of CHD1 and …

Androgen receptor (AR), a ligand-dependent nuclear transcription factor and a member of
steroid hormone receptor family, plays an important role in prostate organogenesis by …

Prostate cancer (PC) initially depends on androgen receptor (AR) signaling for survival and
growth. Therapeutics designed to suppress AR activity serve as the primary intervention for …

The tumor suppressor protein retinoblastoma (RB) is mechanistically linked to suppression
of transcription factor E2F1-mediated cell cycle regulation. For multiple tumor types, loss of …

Androgen receptor (AR) signaling is a key driver of prostate cancer, and androgen-
deprivation therapy (ADT) is a standard treatment for patients with advanced and metastatic …